Spots Global Cancer Trial Database for Docetaxel Plus Oxaliplatin as Therapy in Patients With Pancreatic Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Docetaxel Plus Oxaliplatin as Therapy in Patients With Pancreatic Cancer

Official Title: Phase II Study: Docetaxel Plus Oxaliplatin as Second-line Therapy in Patients With Advanced Metastatic Pancreatic Cancer

Study ID: NCT00690300

Conditions

Pancreas Neoplasms

Interventions

Docetaxel

Oxaliplatin

Study Description

Brief Summary: The purpose of this study is to test a combination-therapy of oxaliplatin and docetaxel in patients with metastatic or locally advanced adenocarcinoma of the pancreas after failure of a palliative first line therapy.

Detailed Description: For years Fluorouracil was the established treatment for pancreatic cancer with median survival times up to 8 months. Since 1997 Gemcitabine is also a standard therapy with in comparison to Fluorouracil a significant better clinical benefit. But after progression of the disease under a palliative first-line therapy there is no established second line therapy for pancreatic cancer. So the purpose of this study is to test the combination of Oxaliplatin and Docetaxel in patients with metastatic or locally advanced adenocarcinoma of the pancreas after failure of a palliative first line therapy to get a reasonable second line concept.